Rexahn Pharmaceuticals, Inc. (RNN) Receives Buy Rating from Seaport Global Securities

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)‘s stock had its “buy” rating reaffirmed by equities research analysts at Seaport Global Securities in a research note issued on Friday, MarketBeat.com reports. They presently have a $13.00 price objective on the stock. Seaport Global Securities’ price objective indicates a potential upside of 367.63% from the company’s previous close.

Several other analysts have also recently weighed in on the company. Rodman & Renshaw restated a “buy” rating and set a $19.50 price target on shares of Rexahn Pharmaceuticals in a report on Friday, June 9th. Zacks Investment Research cut Rexahn Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 18th. HC Wainwright set a $20.00 price target on Rexahn Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, September 11th. Finally, Ifs Securities restated an “outperform” rating on shares of Rexahn Pharmaceuticals in a report on Monday, August 7th. Six investment analysts have rated the stock with a buy rating, Rexahn Pharmaceuticals has a consensus rating of “Buy” and an average price target of $13.85.

Shares of Rexahn Pharmaceuticals (NYSEMKT:RNN) opened at 2.78 on Friday. The firm’s 50-day moving average is $2.37 and its 200-day moving average is $2.26. Rexahn Pharmaceuticals has a one year low of $0.38 and a one year high of $7.10. The company’s market cap is $79.12 million.

ILLEGAL ACTIVITY WARNING: This article was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://ledgergazette.com/2017/10/10/rexahn-pharmaceuticals-inc-rnn-research-coverage-started-at-seaport-global-securities.html.

A number of hedge funds have recently made changes to their positions in RNN. Renaissance Technologies LLC boosted its holdings in Rexahn Pharmaceuticals by 17.6% in the first quarter. Renaissance Technologies LLC now owns 5,758,391 shares of the company’s stock valued at $2,937,000 after acquiring an additional 862,000 shares during the last quarter. Susquehanna International Group LLP bought a new stake in Rexahn Pharmaceuticals in the second quarter valued at approximately $2,905,000. Finally, Sabby Management LLC bought a new stake in Rexahn Pharmaceuticals in the second quarter valued at approximately $706,000.

Rexahn Pharm

Several other analysts have also recently weighed in on the company. Rodman & Renshaw restated a “buy” rating and set a $19.50 price target on shares of Rexahn Pharmaceuticals in a report on Friday, June 9th. Zacks Investment Research cut Rexahn Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 18th. HC Wainwright set a $20.00 price target on Rexahn Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, September 11th. Finally, Ifs Securities restated an “outperform” rating on shares of Rexahn Pharmaceuticals in a report on Monday, August 7th. Six investment analysts have rated the stock with a buy rating, Rexahn Pharmaceuticals has a consensus rating of “Buy” and an average price target of $13.85.

Shares of Rexahn Pharmaceuticals (NYSEMKT:RNN) opened at 2.78 on Friday. The firm’s 50-day moving average is $2.37 and its 200-day moving average is $2.26. Rexahn Pharmaceuticals has a one year low of $0.38 and a one year high of $7.10. The company’s market cap is $79.12 million.

ILLEGAL ACTIVITY WARNING: This article was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://ledgergazette.com/2017/10/10/rexahn-pharmaceuticals-inc-rnn-research-coverage-started-at-seaport-global-securities.html.

A number of hedge funds have recently made changes to their positions in RNN. Renaissance Technologies LLC boosted its holdings in Rexahn Pharmaceuticals by 17.6% in the first quarter. Renaissance Technologies LLC now owns 5,758,391 shares of the company’s stock valued at $2,937,000 after acquiring an additional 862,000 shares during the last quarter. Susquehanna International Group LLP bought a new stake in Rexahn Pharmaceuticals in the second quarter valued at approximately $2,905,000. Finally, Sabby Management LLC bought a new stake in Rexahn Pharmaceuticals in the second quarter valued at approximately $706,000.

Rexahn Pharmaceuticals Company Profile

Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.

Analyst Recommendations for Rexahn Pharmaceuticals (NYSEMKT:RNN)

Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply